---

Immunotherapy in Carcinoma Ovary: A Comprehensive Evidence-Based Overview

---

1. Background: Why Is Ovarian Cancer an "Immunological Challenge"?

Why Ovarian Cancer is "Cold"

---

2. Agents Investigated in Ovarian Cancer

---

3. UPFRONT (FIRST-LINE) SETTING

3A. Rationale for Upfront Immunotherapy

3B. Phase III Trials in the First-Line Setting

IMagyn050 / GOG-3015 / ENGOT-OV39 - Atezolizumab

FIRST / ENGOT-OV44 - Dostarlimab + Niraparib

KEYLYNK-001 / ENGOT-OV43 - Pembrolizumab + Olaparib

NeoPembrOV / GINECO - Pembrolizumab in Neoadjuvant Setting

3C. Meta-Analysis: First-Line Immunotherapy (2026)

---

Flowchart: Upfront ICI Decision Framework

NEWLY DIAGNOSED Advanced Ovarian Cancer (Stage III-IV)
              |
              v
    Standard: Carboplatin + Paclitaxel ± Bevacizumab
    then Maintenance: PARPi ± Bevacizumab (BRCA/HRD-guided)
              |
              v
  Is immunotherapy indicated upfront?
              |
    __________|__________
   |                     |
   NO (Current           INVESTIGATIONAL /
   guidelines 2025-      CLINICAL TRIAL
   2026; no ICI          (consider triplet
   approved in           ICI+PARPi+Bev
   1st line)*            in HRD-positive,
                         BRCA-wt tumors)
   
* Note: ESMO 2025, NCCN, ESGO - No standard ICI in 1st line
* FIRST trial (dostarlimab+niraparib): modest PFS gain, no OS - not guideline-adopted

---

4. RECURRENT SETTING

4A. Platinum-Sensitive Recurrence

JAVELIN Ovarian 100 / JAVELIN Ovarian 200 - Avelumab

Single-Agent ICI in Platinum-Sensitive Disease

---

4B. Platinum-Resistant Recurrence

KEYNOTE-B96 / ENGOT-ov65 - LANDMARK TRIAL ⭐

This is the first ICI-based regimen to achieve regulatory approval in ovarian cancer. It is also the first to show OS benefit in PD-L1-positive platinum-resistant disease.

---

Earlier Phase II Trials in Platinum-Resistant Disease

---

Meta-Analysis: PD-1/PD-L1 in Recurrent/Refractory OC

---

Network Meta-Analysis: Best Combinations

---

Flowchart: Recurrent Setting ICI Decisions

RECURRENT OVARIAN CANCER
         |
    _____|_____
   |           |
Platinum-     Platinum-
Sensitive     Resistant
   |               |
   v               v
ICIs NOT       Check PD-L1 CPS
STANDARD       (IHC 22C3 pharmDx)
(negative            |
trials)         _____|_____
               |           |
             CPS ≥1      CPS <1
               |           |
               v           v
    PEMBROLIZUMAB +    No approved ICI;
    Weekly Paclitaxel  Consider clinical trial
    ± Bevacizumab      (dual checkpoint,
    (FDA/EMA Approved  ADC, etc.)
    Feb/Apr 2026)
    [KEYNOTE-B96]
         |
         v
    1-2 Prior lines only
    OS benefit: 18.2 vs 14.0 mo (HR 0.76) in CPS≥1
    PFS benefit: 8.3 vs 6.4 mo (HR 0.70) ITT

---

5. RATIONALE FOR COMBINING IMMUNOTHERAPY WITH PARP INHIBITORS

5A. Mechanistic Synergy: How PARPi "Heats Up" the TME

i. cGAS-STING Pathway Activation

• PARPi cause accumulation of cytosolic double-stranded DNA (dsDNA) fragments due to impaired DNA repair
• These dsDNA fragments activate cyclic GMP-AMP synthase (cGAS), which produces the second messenger cGAMP
• cGAMP activates STING (Stimulator of Interferon Genes) on immune cells
• STING signals via IRF3 and NF-κB to produce Type I interferons (IFN-α/β) and pro-inflammatory cytokines
• Result: innate immune activation, dendritic cell maturation, enhanced antigen presentation

ii. Increased Tumor Immunogenicity

• Stalled replication forks and DSBs from PARPi cause genomic instability
• This increases neoantigen burden from somatic mutations
• Upregulates MHC-I expression on tumor cells - improving T-cell recognition
• Promotes NK cell-mediated killing via NKG2D ligand upregulation

iii. Immunosuppressive Signal Reduction

• PARPi reduce expression of TGF-β and VEGF (co-produced by tumor cells)
• Decrease tumor-associated macrophage (TAM) polarization toward M2 (immunosuppressive) phenotype
• BRCA/HRD-mutated tumors have higher TMB - more neoantigens

iv. PD-L1 Upregulation by PARPi

• PARPi upregulate PD-L1 expression on tumor cells via cGAS-STING-IFN signaling
• This creates an adaptive resistance mechanism that ICI can then block
• Paradox: PARPi create the very signal (PD-L1) that makes tumor cells visible AND vulnerable to PD-1/PD-L1 blockade - a prime opportunity for ICI

v. Treg and MDSC Modulation

• PARPi reduce tumor-infiltrating Foxp3+ Tregs and MDSCs
• Shift TME from suppressive to effector-dominant phenotype

---

Summary Diagram: PARPi-ICI Mechanistic Synergy

PARPi (olaparib/niraparib/rucaparib)
         |
         v
  DNA damage accumulation
  (stalled forks, DSBs)
         |
    _____|_____
   |           |
   v           v
cGAS-STING   Neoantigen
activation   generation
   |           |
   v           v
Type I IFN   MHC-I upregulation
   |           |
   v           v
DC activation → T-cell priming
   |
   v
PD-L1 upregulation on tumor cell
   |
   v
ICI (anti-PD-1/PD-L1) BLOCKS PD-L1
   |
   v
Restored T-cell killing of tumor

---

5B. Clinical Trials: ICI + PARPi Combinations

PAOLA-1 / ENGOT-ov25 - Durvalumab + Olaparib + Bevacizumab (Maintenance)

FIRST / ENGOT-OV44 (Detailed - see above, Section 3B)

• Dostarlimab + niraparib: HR 0.85 PFS, no OS benefit

KEYLYNK-001 / ENGOT-OV43

• Pembrolizumab + olaparib in first-line: negative in ITT

DUO-O / ENGOT-OV46 - Durvalumab + Olaparib + Bevacizumab (Frontline)

Tremelimumab + Olaparib (Recurrent)

• Tremelimumab ± olaparib in recurrent EOC
• Limited clinical activity; tolerable safety
• No significant improvement over olaparib alone

---

5C. Biomarker Interactions in PARPi + ICI Combinations

---

6. COMPREHENSIVE TABLE: ALL MAJOR PHASE III ICI TRIALS IN OVARIAN CANCER

---

7. BIOMARKER SELECTION: WHOM TO TREAT?

Patient with Ovarian Cancer - Considering ICI
                    |
           _________|_________
          |                   |
    FIRST-LINE          RECURRENT/RELAPSED
          |                   |
   No approved ICI      |
   (all guidelines      v
   2025-2026)    Test PD-L1 (CPS, 22C3 assay)
                        |
               _________|_________
              |                   |
           CPS ≥1              CPS <1
              |                   |
    KEYNOTE-B96 regimen:    No approved ICI;
    Pembrolizumab +         Enroll in clinical trial
    weekly paclitaxel ±
    bevacizumab
    (Platinum-resistant,
     1-2 prior lines)
              |
    Check BRCA/HRD status for
    PARPi combination decisions

---

8. CURRENT GUIDELINES: IMMUNOTHERAPY IN OVARIAN CANCER (2025-2026)

Summary of Guidelines (as of June 2026)

Critical Point (as of June 2026): Per the systematic guideline comparison (PMC12730224, updated August 2025): "None of the major international guidelines have incorporated immunotherapy into their standard treatment recommendations for advanced ovarian cancer" - this has since changed for the platinum-resistant setting with the FDA/EMA approval of pembrolizumab + paclitaxel (KEYNOTE-B96).

Companion Diagnostic Requirement (FDA)

• PD-L1 IHC 22C3 pharmDx (Agilent Technologies) is the FDA-approved companion diagnostic
• CPS ≥1 required for pembrolizumab use in platinum-resistant EOC
• CPS = (PD-L1-staining tumor cells + lymphocytes + macrophages) / total viable tumor cells × 100

---

9. SPECIAL CONTEXT: OVARIAN CLEAR CELL CARCINOMA (OCCC)

• Higher TMB and MSI rate compared to HGSOC
• More frequent PIK3CA mutations, ARID1A mutations (BAF complex) - potential ICI sensitizers
• Chemo-resistant histology - making ICI a more attractive option
• Retrospective and early-phase data suggest higher ICI response rates (~20-30%)
• Emerging subtype for enriched ICI trials (Wu et al. 2026, PMID 42362076)

---

10. ADVERSE EFFECTS OF ICI IN OVARIAN CANCER

---

11. FUTURE DIRECTIONS AND ONGOING TRIALS

---

12. KEY META-ANALYSIS SUMMARY (2026) - WHAT DO RCTs TELL US?

---

13. CLINICAL SUMMARY AND PRACTICAL ALGORITHM

Who benefits from ICI in ovarian cancer? (Evidence-Based 2026)

PATIENT WITH OVARIAN CANCER
            |
    ________|_________
   |                  |
1st LINE          RECURRENT
   |                  |
NO ICI           Platinum-sensitive?
standard              |
(trials            NO ICI standard
negative)          (negative trials)
                      |
                  Platinum-resistant?
                      |
              Test PD-L1 (CPS 22C3)
                      |
              ________|________
             |                 |
          CPS ≥1           CPS <1
             |                 |
     Pembrolizumab         Clinical trial
     + Paclitaxel          OR other options:
     ± Bevacizumab         - Mirvetuximab (FRα+)
     (1-2 prior lines)     - Relacorilant+nabPCX
     [FDA Approved         - Liposomal doxorubicin
      Feb 2026]            - Topotecan
             |                 - Gemcitabine
     PARPi-naive?
     Check BRCA/HRD
     for PARPi eligibility
     (complementary,
      not concurrent)

---

Summary: Key Evidence Points

1. Ovarian cancer is an immunologically "cold" tumor - single-agent ICI has ~7% ORR in unselected recurrent disease.
2. First-line ICI trials are largely negative (IMagyn050 negative; FIRST trial positive for PFS only with HR 0.85 but no OS benefit). No ICI is currently standard in first-line therapy per NCCN/ESMO/ESGO 2025-2026.
3. KEYNOTE-B96 is the game-changing trial - pembrolizumab + weekly paclitaxel ± bevacizumab received FDA approval (Feb 10, 2026) and EMA approval (Apr 2, 2026) for platinum-resistant recurrent EOC with PD-L1 CPS ≥1, 1-2 prior lines. It is the first ICI approval in ovarian cancer.
4. PARPi + ICI combination rationale is strong biologically (cGAS-STING activation, PD-L1 upregulation, neoantigen generation) but clinically, the benefit is modest and biomarker-restricted. The triplet (ICI+PARPi+bevacizumab) shows the best PFS HR (0.71) in selected subgroups.
5. Best biomarkers: PD-L1 CPS ≥1 (required for pembrolizumab approval), HRD+/BRCA-wt (PARPi+ICI signal), multidimensional TME profiling (CD8:Treg, Immunoscore) represent the future.
6. OCCC is an immunologically distinct subtype that may respond better to ICI.
7. Safety: Grade ≥3 TRAEs are significant (~67% with combination), requiring careful patient selection and monitoring.

---

References

• Vida R et al. Meta-analysis of anti-PD-1/PD-L1 in advanced OC. Cancer Treat Rev 2026. PMID 41763143
• Marchetti C et al. First-line ICI ± PARPi meta-analysis. Crit Rev Oncol Hematol 2026. PMID 42155872
• Colombo N et al. KEYNOTE-B96. The Lancet 2026. PMID 41974150
• Hardy-Bessard AC et al. FIRST/ENGOT-OV44 (dostarlimab+niraparib). Ann Oncol 2025. PMID 40461381
• Bogani G, Moore KN et al. ICI in epithelial OC systematic review. Gynecol Oncol 2025. PMID 39764856
• Zeng S et al. PD-1/PD-L1 in recurrent OC meta-analysis. Front Pharmacol 2023. PMID 36992842
• Ahmadi N et al. Network meta-analysis PD-1/PD-L1 OC. Future Oncol 2025. PMID 40650991
• Wu T et al. Beyond the "cold" barrier. Crit Rev Oncol Hematol 2026. PMID 42362076
• FDA Approval Notice, Feb 10, 2026
• PMC Guideline Comparison (AIOM-BGCS-ESGO-ESMO-JGSO-NCCN-NICE). Updated August 2025. PMC12730224
• Hinchcliff EM et al. Tremelimumab+durvalumab RCT. Cancer 2024. PMID 38009662
• Collet L et al. NeoPembrOV TME analysis. Clin Cancer Res 2025. PMID 40378056This is a detailed, fully evidence-based overview. Here is a concise orientation to the content above:

---

Quick Orientation

---

Key Takeaways at a Glance

The Fundamental Problem

The PARPi+ICI Story